CLS conducted a rights issue of units during the period 23 August 2022 - 6 September 2022, which provided the Company approximately SEK 55.4 million, before deduction of transaction related costs. A total of 55,455,240 B-shares and 27,722,620 warrants of series TO 5 B have been issued through the rights issue. The rights issue has now been registered with the Swedish Companies Registration Office, and the last day of trading in BTU will be on 5 October and stop day will be 7 October 2022.The new B-shares and warrants of series TO 5 B are estimated to be delivered to each shareholder's account on 11 October 2022.

After the registration, the total number of shares in CLS amounts to 124,751,791 shares, 600,000 A-shares and 124,151,791 B-shares, and the share capital amounts to approximately SEK 11,539,540.73. In addition, there are 27,722,620 outstanding warrants of series TO 5 B. The newly issued warrants of series TO 5 B will be traded on Nasdaq First North Growth Market and the first day of trading will be on 11 October 2022. Warrants of series TO 5 B have ISIN code SE0018408130 and will be traded under the ticker "CLS TO 5 B".

Summary terms of warrants of series TO 5 B

Each warrant of series TO 5 B entitles the holder to subscribe for one (1) new B-share in CLS during the period starting from 14 February 2023 until and including 28 February 2023. The subscription price in the following warrant exercise amounts to seventy (70) percent of the average volume-weighted price for the B-share according to Nasdaq First North Growth Market's official price statistics during a period of ten (10) trading days ending two (2) banking days before the exercise period begins. The Company will publish the subscription price the day before the first day of the exercise period. The subscription price must be rounded to the nearest whole Swedish öre and may not exceed SEK 1.00 per new B-share and must not fall below the share's quota value. If the warrants of series TO 5 B are fully exercised to the highest price, the Company can be provided an additional maximum of approximately SEK 27.7 million before deduction of transaction related costs. The complete terms and conditions for warrants of series TO 5 B is available on the Company's website (www.clinicallaser.se).

Advisors

In connection with the rights issue, Sedermera Corporate Finance AB has acted as financial advisor, Markets & Corporate Law Nordic AB as legal advisor and Nordic Issuing AB as issuing agent. Shark Communication AB has assisted the Company with advice regarding communication.

For further information about the rights issue, please contact:

Sedermera Corporate Finance

Phone: +46 40615 14 10

E-mail: cf@sedermera.se

www.sedermera.se

For more information about CLS, please contact:

Dan J. Mogren, CEO

Phone: +46 (0) 70-590 11 40

E-mail: dan.mogren@clinicallaser.com

www.clinicallaser.se

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

Certified Adviser

FNCA Sweden AB

Phone: +46 8528 00399

E-mail: info@fnca.se

About CLS and TRANBERG system

Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG® | Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment imILT®,the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8528 00399. E-mail: info@fnca.se.

For more information about CLS, please visit the Company's website: www.clinicallaser.se